22:39 , Mar 29, 2019 |  BioCentury  |  Finance

ORI goes oncolytic

Oncolytic virus company Cold Genesys continues to draw East Asian investors on the back of its data in bladder cancer. ORI Healthcare Fund L.P.'s Simone Song said the Hong Kong fund had been following Cold...
19:41 , Dec 14, 2018 |  BC Week In Review  |  Financial News

WuXi AppTec unchanged in first day of trading on Hong Kong exchange

Shares of WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) were unchanged in the first day of trading in Hong Kong Dec. 13, closing at HK$68. WuXi AppTec priced the offering at HK$68, near the middle of...
22:02 , Dec 7, 2018 |  BC Extra  |  Financial News

WuXi AppTec prices Hong Kong offering in stormy market

Despite global trade headwinds and a choppy market for biopharma stocks in China, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) managed to price its Hong Kong listing within its proposed range Friday, potentially raising HK$7.9 billion...
19:07 , Dec 7, 2018 |  BC Week In Review  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
23:31 , Dec 6, 2018 |  BC Extra  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
21:58 , Sep 21, 2018 |  BioCentury  |  Finance

Funding WuXi’s expansion

WuXi AppTec Co. Ltd. (Shanghai:603259) is showing no signs of slowing down. The company is the largest R&D services platform in Asia, and a planned dual listing in Hong Kong that could bring in as...
03:53 , Sep 21, 2018 |  BC Innovations  |  Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Financial News

I-Mab raises $220M in series C

I-Mab Biopharma (Shanghai, China) raised $220 million June 29 in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past...
23:28 , Jul 11, 2018 |  BC Extra  |  Company News

Ally Bridge invests in Tasly Biopharmaceuticals

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) said Wednesday it issued 75.7 million new shares, representing about 7% of the company, as it prepares for a possible IPO. The investors, which include Ally Bridge LB Healthcare...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...